Spring Bank Pharmaceuticals to present HBV and HCV treatment candidate

Spring Bank Pharmaceuticals to present HBV and HCV treatment results | Courtesy of
Spring Bank Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that creates novel therapeutics to treat viral infections, has recently announced that a company representative will present its lead drug candidate, SB 9200, for treating infections of hepatitis B virus (HBV) and hepatitis C virus (HCV).

These poster presentations will be given at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26. This year marks 50 years that health professionals have gathered at this convention.

Stephan Menne, from Georgetown University Medical Center's department of microbiology and immunology will make a presentation about SB 9200 on April 25. His presentation will discuss the effectiveness and introduction of SB 9200 to a body’s immune system.

There will be other poster presentations about SB 9200 at the congress as well.

“We are very pleased to have been selected to present our HBV preclinical data and HCV Phase I data at the upcoming EASL meeting,” Spring Bank Chief Scientific Officer Radhakrishnan KIyer said. “This congress affords us the opportunity to highlight our drug development programs in two difficult-to-treat viral infections to the worldwide medical and scientific communities.”